---
title: "BAVA: Upgraded 2026 guidance to DKK 5.7B revenue, 30% EBITDA margin, and announced DKK 750M buyback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296629105.md"
description: "H1 2026 revenue exceeded DKK 3 billion with 35% EBITDA margin, driven by strong Travel Health and Public Preparedness growth. Full-year guidance was upgraded to DKK 5.7 billion revenue and 30% EBITDA margin, with a new DKK 750 million share buyback announced.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-21T14:13:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296629105.md)
  - [en](https://longbridge.com/en/news/296629105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296629105.md)
generator: "portal-rs"
---

# BAVA: Upgraded 2026 guidance to DKK 5.7B revenue, 30% EBITDA margin, and announced DKK 750M buyback

H1 2026 revenue exceeded DKK 3 billion with 35% EBITDA margin, driven by strong Travel Health and Public Preparedness growth. Full-year guidance was upgraded to DKK 5.7 billion revenue and 30% EBITDA margin, with a new DKK 750 million share buyback announced.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BVNRY.US](https://longbridge.com/en/quote/BVNRY.US.md)

## Related News & Research

- [BAVA: Upgraded 2026 guidance after strong H1 revenue and profitability, led by Travel Health growth](https://longbridge.com/en/news/296572886.md)
- [MNY: Adjusted EBITDA loss narrowed and new high-margin products launched, supporting profitable growth](https://longbridge.com/en/news/298737733.md)
- [SOM: Revenue up 22%, EBITDA up 59%, guidance raised, and share buybacks expanded](https://longbridge.com/en/news/298269060.md)
- [TIG: Returned to operating profit with strong EBITDA growth and strategic review nearing completion](https://longbridge.com/en/news/298178752.md)
- [Omada Health targets at least 20% annual revenue growth, 30% adjusted EBITDA margin long term](https://longbridge.com/en/news/298600874.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**